Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due to its slow growing nature and reduced symptoms. Increased risk factors ...

Share on Pinterest A study in mice investigates the potential of an immunotherapy-dietary supplement combo in treating prostate cancer. Image credit: Don Wu/Getty Images. About 13% of cisgender men ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. Black men with ...

Immunotherapy for stage 4 prostate cancer is revolutionizing the way advanced disease is being treated, offering hope for patients worldwide. Unlike conventional treatment methods such as surgery and ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is ...

FORT LAUDERDALE, Fla., April 29, 2026 (GLOBE NEWSWIRE)-- Syncromune®, Inc., a clinical-stage biopharmaceutical company advancing SYNC-T™, an investigational platform combination immunotherapy for ...

PHOENIX — A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may ...